scholarly journals Long-term follow-up of choroidal neovascularization secondary to angioid streaks: case series and literature review

2012 ◽  
pp. 1029 ◽  
Author(s):  
Saba Saba Al Rashaed ◽  
Fernando Arevalo
2017 ◽  
Vol 238 (1-2) ◽  
pp. 44-51 ◽  
Author(s):  
Giovanni Giacomelli ◽  
Lucia Finocchio ◽  
Ilaria Biagini ◽  
Andrea Sodi ◽  
Vittoria Murro ◽  
...  

2016 ◽  
Vol Volume 11 ◽  
pp. 23-30 ◽  
Author(s):  
Maria Martinez-Serrano ◽  
Abelardo Rodriguez-Reyes ◽  
Jose Luis Guerrero-Naranjo ◽  
Guillermo Salcedo-Villanueva ◽  
Jans Fromow-Guerra ◽  
...  

2014 ◽  
Vol 25 (1) ◽  
pp. 47-50 ◽  
Author(s):  
Chiara Rosina ◽  
Mary Romano ◽  
Mario Cigada ◽  
Laura de Polo ◽  
Giovanni Staurenghi ◽  
...  

Author(s):  
Nikolaos Kougkas ◽  
George Bertsias ◽  
Ioannis Papalopoulos ◽  
Argiro Repa ◽  
Prodromos Sidiropoulos ◽  
...  

Author(s):  
Liana Tripto-Shkolnik ◽  
Yair Liel ◽  
Naama Yekutiel ◽  
Inbal Goldshtein

AbstractDenosumab discontinuation is associated with rapid reversal of bone turnover suppression and with a considerable increase in fracture risk, including a risk for multiple vertebral fractures (MVF). Long-term follow-up of patients who sustained MVF after denosumab discontinuation has not been reported. This case-series was aimed to provide a long-term follow-up on the management and outcome of denosumab discontinuers who initially presented with multiple vertebral fractures. Denosumab discontinuers were identified from a computerized database of a large healthcare provider. Baseline and follow-up clinical, laboratory, and imaging data were obtained from the computerized database and electronic medical records. The post-denosumab discontinuers MVF patients consisted of 12 women aged 71±12. Osteoporotic fractures were prevalent before denosumab discontinuation in 6 of the patients. The majority received bisphosphonates before denosumab. MVF occurred 134±76 days after denosumab discontinuation. The patients were followed for a median of 36.5 (IQR 28.2, 42.5) months after MVF. Two patients passed-away. Two patients suffered recurrent vertebral fractures. Following MVF, patients were treated inconsistently with denosumab, teriparatide, oral, and intravenous bisphosphonates, in various sequences. Two patients underwent vertebroplasty/kyphoplasty. This long-term follow-up of real-world patients with MVF following denosumab discontinuation reveals that management is inconsistent, and recurrent fractures are not uncommon. It calls for clear management guidelines for patients with MVF after denosumab discontinuation and for special attention to this high-risk group.


Dermatology ◽  
2021 ◽  
pp. 1-7
Author(s):  
Jurr Boer

<b><i>Background:</i></b> Patients with hidradenitis suppurativa (HS) are still often disappointed with the current treatments offered and there is a clear demand for more effective options. Since the late 1990s there has been a revival in the use of radiotherapy (RT) for different benign diseases, including HS. During the past 20 years one case series and some scattered case reports have described promising results of RT. <b><i>Objectives:</i></b> To evaluate the long-term efficacy of RT in early-stage HS. <b><i>Methods:</i></b> A postal survey-based long-term follow-up with simple factual questions of partly retrospective and partly contemporary characteristics was performed. Sixty-four patients (96 axillae), diagnosed with mild to moderate HS were irradiated with a orthovoltage unit with 100 kV, 3 mm Al or 200 kV, 0.5 Cu filtering, respectively. Four to six biweekly fractional doses ranging from 0.75 to 1 Gy up to a total dose of 6 Gy in one series, and in chronic cases followed by four daily fractions of 2 Gy up to a total dose of 14 Gy, were given. Late treatment toxicity and the rate of remission of the disease were evaluated. <b><i>Results:</i></b> The overall response rate of the survey was 64.1% with 40.6% (26/64) valid, complete questionnaires. In total, 40 axillae were irradiated in these 26 patients. After a median follow-up of 40 years (range 32–52) complete remission of the lesions occurred in 34 of the 40 sites (85%). None of the 26 patients with 40 irradiated sites reported adverse effects at the time of the survey. <b><i>Conclusions:</i></b> RT appears to be an effective treatment for early and mild HS in the majority of patients. In this case series, no side effects were reported after a median follow-up period of 40 years.


Sign in / Sign up

Export Citation Format

Share Document